The companies expect to complete the submission of the NDA for treatment of MDD in the second half of 2022; associated filing for postpartum depression is anticipated in the first half of 2023
The business is a recognized leader in managing Covid-19 and mRNA research programs
Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers releases guidelines for the scheme
Acute therapies continue to report strong growth compared to chronic ones.
Following the pre-NDA meeting with the U.S. FDA, the companies confirmed the current efficacy and safety databases are expected to be adequate for filing with confirmed pathways for MDD and PPD
Subscribe To Our Newsletter & Stay Updated
